SCHEMBL4639142

SCHEMBL4639142

Cc1cccc(C)c1NC(=O)COc1cccc2cccnc12

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 2/20 0.70
L3MBTL1 Q9Y468 3/20 0.69
NPC1 O15118 3/20 0.69
RAB9A P51151 3/20 0.69
SMN1; SMN2 Q16637 3/20 0.69
MAPT P10636 6/20 0.66
ALDH1A1 P00352 3/20 0.66
POLB P06746 3/20 0.66
BLM P54132 1/20 0.66
TP53 P04637 2/20 0.63
HPGD P15428 1/20 0.63
RXFP1 Q9HBX9 2/20 0.58
NOTUM Q6P988 2/20 0.56
MEN1 O00255 1/20 0.55
MPI P34949 1/20 0.55
KMT2A Q03164 1/20 0.55
GAA P10253 2/20 0.55
LMNA P02545 1/20 0.54
SCN5A Q14524 1/20 0.53
KDM4E B2RXH2 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8628518 0.82 SMN1; SMN2 (1.00) SCN9AL3MBTL1NPC1RAB9ASMN1; SMN2
SCHEMBL28678208 0.80 MAPT (1.00) L3MBTL1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL8871046 0.78 MAPT (0.67) L3MBTL1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL4619352 0.78 NPC1 (0.70) SCN9AL3MBTL1NPC1RAB9ASMN1; SMN2
SCHEMBL4619288 0.77 MAPT (0.60) SCN9AL3MBTL1NPC1RAB9ASMN1; SMN2
SCHEMBL8625603 0.77 MAPT (0.62) L3MBTL1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL5227497 0.76 CYP3A4 (0.72) SCN9ASMN1; SMN2ALDH1A1BLMMEN1
SCHEMBL9284192 0.76 MAPT (0.68) L3MBTL1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL45506 0.76 MAPT (0.68) L3MBTL1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL15818384 0.76 MAPT (0.60) L3MBTL1NPC1RAB9ASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080166310-A1 Administration of 2-oxyacetamide compounds for promoting and/or inducing and/or stimulating the pigmentation of keratin materials and/or for limiting the depigmentation and/or bleaching thereof L'OREAL (FR) 2008-07-10 US disclosed
US-20080166310-A1 Administration of 2-oxyacetamide compounds for promoting and/or inducing and/or stimulating the pigmentation of keratin materials and/or for limiting the depigmentation and/or bleaching thereof L'OREAL (FR) 2008-07-10 US disclosed
US-20080166310-A1 Administration of 2-oxyacetamide compounds for promoting and/or inducing and/or stimulating the pigmentation of keratin materials and/or for limiting the depigmentation and/or bleaching thereof L'OREAL (FR) 2008-07-10 US disclosed
EP-1888017-A1 USE OF-OXYACETAMIDE COMPOUNDS FOR PROMOTING AND/OR INDUCING AND/OR STIMULATING THE PIGMENTATION OF KERATIN MATERIALS AND/OR FOR LIMITING THEIR DEPIGMENTATION AND/OR BLEACHING L'Oréal (FR) 2008-02-20 EP disclosed
US-20070092467-A1 Oxyacetamide compounds useful for stimulating or inducing the growth and/or retarding the loss of keratin fibers L'OREAL (FR) 2007-04-26 US disclosed
US-20070092467-A1 Oxyacetamide compounds useful for stimulating or inducing the growth and/or retarding the loss of keratin fibers L'OREAL (FR) 2007-04-26 US disclosed
US-20070092467-A1 Oxyacetamide compounds useful for stimulating or inducing the growth and/or retarding the loss of keratin fibers L'OREAL (FR) 2007-04-26 US disclosed
EP-1763382-A1 2-OXY-ACETAMIDE COMPOUND, THE USES THEREOF AND COMPOSITIONS FOR STIMULATING OR INDUCING THE GROWTH, AND/OR RETARDING THE LOSS, OF KERATIN FIBRES L'OREAL (FR) 2007-03-21 EP disclosed
WO-2006131282-A1 USE OF-OXYACETAMIDE COMPOUNDS FOR PROMOTING AND/OR INDUCING AND/OR STIMULATING THE PIGMENTATION OF KERATIN MATERIALS AND/OR FOR LIMITING THEIR DEPIGMENTATION AND/OR BLEACHING L'ORÉAL (FR) 2006-12-14 WO disclosed
WO-2005107687-A1 2-OXY-ACETAMIDE COMPOUND, THE USES THEREOF AND COMPOSITIONS FOR STIMULATING OR INDUCING THE GROWTH, AND/OR RETARDING THE LOSS, OF KERATIN FIBRES L'OREAL (FR) 2005-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070092467-A1 Oxyacetamide compounds useful for stimulating or inducing the growth and/or retarding the loss of keratin fibers HPGD, KRT18, PTGS1 SCN9A 2115/4885L3MBTL1 4657/4885NPC1 4052/4885
US-20080166310-A1 Administration of 2-oxyacetamide compounds for promoting and/or inducing and/or stimulating the pigmentation of keratin materials and/or for limiting the depigmentation and/or bleaching thereof KRT18, TYR, CRYAA SCN9A 434/4885L3MBTL1 3737/4885NPC1 4047/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.